{"id":390247,"date":"2020-12-01T06:03:16","date_gmt":"2020-12-01T11:03:16","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=390247"},"modified":"2020-12-01T06:03:16","modified_gmt":"2020-12-01T11:03:16","slug":"tearclear-announces-successful-completion-of-pre-ind-meeting-with-the-fda-for-a-preservative-free-multi-dose-delivery-of-latanoprost-for-the-treatment-of-glaucoma","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tearclear-announces-successful-completion-of-pre-ind-meeting-with-the-fda-for-a-preservative-free-multi-dose-delivery-of-latanoprost-for-the-treatment-of-glaucoma\/","title":{"rendered":"TearClear Announces Successful Completion of Pre-IND Meeting with the FDA for a Preservative Free Multi-Dose Delivery of Latanoprost for the Treatment of Glaucoma"},"content":{"rendered":"<h2>\nPrepared to file an IND in mid-2021 via the 505(b)(2) NDA pathway<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"left\">BOSTON, Dec.  01, 2020  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sSlaavR811jx3S9qOHW_JIQ1MlsRRSCcl0rpLa1x218wZdCXD3FMX--cplKnOOOWK9Edr1pFTlFwOlCvBRVQ0Q==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">TearClear<\/a>, an emerging ophthalmic pharmaceutical company, today announced successful completion of pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding the development plan for the preservative free multi-dose delivery of a proprietary Latanoprost formulation, including the clinical study design for the registration study.<\/p>\n<p>\u201cWe are pleased with the outcome of the Pre-IND meeting and look forward to preparing the IND filing and commencing our pivotal registration trial in 2021,\u201d said\u00a0Robert Dempsey, Chief Executive Officer, TearClear. &#8220;The successful completion of this engagement with the FDA is an important milestone for the company and provides clarity and confidence as we advance our lead clinical program in the U.S.&#8221;<\/p>\n<p>\n        <strong>About the 505(b)(2) Pathway<\/strong>\n      <\/p>\n<p>Section 505(b)(2) of the U.S. Federal Food, Drug, and Cosmetic Act permits the FDA to approve a New Drug Application (NDA) in part on the basis of published literature and\/or a previous agency finding as to the safety or effectiveness of a drug. A 505(b)(2) NDA can be utilized for new chemical entities or for changes to previously approved drugs. This pathway potentially allows for a more rapid development and approval timeline compared to new chemical\/molecular entities, based in part by referencing this information.<\/p>\n<p>\n        <strong>About Preservative Free<\/strong>\n      <\/p>\n<p>Preservatives, such as\u00a0benzalkonium chloride\u00a0(BAK), are necessary in ophthalmic solutions to maintain sterility.\u00a0However, on the ocular surface, they have been reported to be associated with\u00a0adverse effects like\u00a0hyperemia, tear film instability and conjunctival inflammation potentially leading to meibomian gland dysfunction (MGD). By removing preservatives from the ocular surface, the potential for long term\u00a0deleterious effects on the eye are reduced.\u00a0TearClear\u2019s technology offers the only means of delivering a preservative-free dose directly from preserved solutions.<\/p>\n<p>\n        <strong>About TearClear<\/strong>\n      <\/p>\n<p>TearClear is an emerging ophthalmic pharmaceutical company with the goal of disrupting the way current topical medications are delivered to the ocular surface.\u00a0Our lead product candidates in glaucoma will pave the way for future indications across multiple\u00a0programs in development. This first in class\u00a0platform of drugs enables medication delivery to ultimately enhance patient safety and compliance by capturing preservatives before they reach the ocular surface.\u00a0TearClear is based in Boston, MA. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sSlaavR811jx3S9qOHW_JE8BMTAZt5EuV9rYlxjgloCnNF6I5ZSBp0AIPpeKKQKk5sVYs_Bc7SW9pNzd7HTJzw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">TearClear<\/a> and connect with us on LinkedIn: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cN7hdQ7fnBDQVTKv9Hfr7bKxnIvDN11rUA39EGmIIOU1UCtVBKFh-go0SqUctAEFQxag-bhrjrD69yyQ71a88RCqHXMdsr4YO5a84Jt7DKIL_OI9RSpTbk3TOaK7soke\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>Contact:<br \/>Patrick Crowley<br \/>TearClear<br \/>859-462-4245<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SJ0STdMQamgHGZg0BmL4M9oFuOhTnmyRPNL7PMUyOi9G9I3SsdR9qNEciA5dA-vJzDaLGesl4IdyHUE3kra1C6NgKfyLtOtS8bk-nZeGmaPK2C9ZzZ22DItNLpwZSP2-\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">pcrowley@strategicadvisersllc.com<\/a><\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5Mzk0OSMzODQ4NTg1IzIwODc3MjU=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/babc650c-7ffa-4e57-abee-af665445ad41\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Prepared to file an IND in mid-2021 via the 505(b)(2) NDA pathway BOSTON, Dec. 01, 2020 (GLOBE NEWSWIRE) &#8212; TearClear, an emerging ophthalmic pharmaceutical company, today announced successful completion of pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding the development plan for the preservative free multi-dose delivery of a proprietary Latanoprost formulation, including the clinical study design for the registration study. \u201cWe are pleased with the outcome of the Pre-IND meeting and look forward to preparing the IND filing and commencing our pivotal registration trial in 2021,\u201d said\u00a0Robert Dempsey, Chief Executive Officer, TearClear. &#8220;The successful completion of this engagement with the FDA is an important milestone for the company and provides clarity and confidence &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tearclear-announces-successful-completion-of-pre-ind-meeting-with-the-fda-for-a-preservative-free-multi-dose-delivery-of-latanoprost-for-the-treatment-of-glaucoma\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;TearClear Announces Successful Completion of Pre-IND Meeting with the FDA for a Preservative Free Multi-Dose Delivery of Latanoprost for the Treatment of Glaucoma&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-390247","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>TearClear Announces Successful Completion of Pre-IND Meeting with the FDA for a Preservative Free Multi-Dose Delivery of Latanoprost for the Treatment of Glaucoma - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tearclear-announces-successful-completion-of-pre-ind-meeting-with-the-fda-for-a-preservative-free-multi-dose-delivery-of-latanoprost-for-the-treatment-of-glaucoma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TearClear Announces Successful Completion of Pre-IND Meeting with the FDA for a Preservative Free Multi-Dose Delivery of Latanoprost for the Treatment of Glaucoma - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Prepared to file an IND in mid-2021 via the 505(b)(2) NDA pathway BOSTON, Dec. 01, 2020 (GLOBE NEWSWIRE) &#8212; TearClear, an emerging ophthalmic pharmaceutical company, today announced successful completion of pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding the development plan for the preservative free multi-dose delivery of a proprietary Latanoprost formulation, including the clinical study design for the registration study. \u201cWe are pleased with the outcome of the Pre-IND meeting and look forward to preparing the IND filing and commencing our pivotal registration trial in 2021,\u201d said\u00a0Robert Dempsey, Chief Executive Officer, TearClear. &#8220;The successful completion of this engagement with the FDA is an important milestone for the company and provides clarity and confidence &hellip; Continue reading &quot;TearClear Announces Successful Completion of Pre-IND Meeting with the FDA for a Preservative Free Multi-Dose Delivery of Latanoprost for the Treatment of Glaucoma&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/tearclear-announces-successful-completion-of-pre-ind-meeting-with-the-fda-for-a-preservative-free-multi-dose-delivery-of-latanoprost-for-the-treatment-of-glaucoma\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-01T11:03:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5Mzk0OSMzODQ4NTg1IzIwODc3MjU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tearclear-announces-successful-completion-of-pre-ind-meeting-with-the-fda-for-a-preservative-free-multi-dose-delivery-of-latanoprost-for-the-treatment-of-glaucoma\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tearclear-announces-successful-completion-of-pre-ind-meeting-with-the-fda-for-a-preservative-free-multi-dose-delivery-of-latanoprost-for-the-treatment-of-glaucoma\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"TearClear Announces Successful Completion of Pre-IND Meeting with the FDA for a Preservative Free Multi-Dose Delivery of Latanoprost for the Treatment of Glaucoma\",\"datePublished\":\"2020-12-01T11:03:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tearclear-announces-successful-completion-of-pre-ind-meeting-with-the-fda-for-a-preservative-free-multi-dose-delivery-of-latanoprost-for-the-treatment-of-glaucoma\\\/\"},\"wordCount\":421,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tearclear-announces-successful-completion-of-pre-ind-meeting-with-the-fda-for-a-preservative-free-multi-dose-delivery-of-latanoprost-for-the-treatment-of-glaucoma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5Mzk0OSMzODQ4NTg1IzIwODc3MjU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tearclear-announces-successful-completion-of-pre-ind-meeting-with-the-fda-for-a-preservative-free-multi-dose-delivery-of-latanoprost-for-the-treatment-of-glaucoma\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tearclear-announces-successful-completion-of-pre-ind-meeting-with-the-fda-for-a-preservative-free-multi-dose-delivery-of-latanoprost-for-the-treatment-of-glaucoma\\\/\",\"name\":\"TearClear Announces Successful Completion of Pre-IND Meeting with the FDA for a Preservative Free Multi-Dose Delivery of Latanoprost for the Treatment of Glaucoma - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tearclear-announces-successful-completion-of-pre-ind-meeting-with-the-fda-for-a-preservative-free-multi-dose-delivery-of-latanoprost-for-the-treatment-of-glaucoma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tearclear-announces-successful-completion-of-pre-ind-meeting-with-the-fda-for-a-preservative-free-multi-dose-delivery-of-latanoprost-for-the-treatment-of-glaucoma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5Mzk0OSMzODQ4NTg1IzIwODc3MjU=\",\"datePublished\":\"2020-12-01T11:03:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tearclear-announces-successful-completion-of-pre-ind-meeting-with-the-fda-for-a-preservative-free-multi-dose-delivery-of-latanoprost-for-the-treatment-of-glaucoma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tearclear-announces-successful-completion-of-pre-ind-meeting-with-the-fda-for-a-preservative-free-multi-dose-delivery-of-latanoprost-for-the-treatment-of-glaucoma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tearclear-announces-successful-completion-of-pre-ind-meeting-with-the-fda-for-a-preservative-free-multi-dose-delivery-of-latanoprost-for-the-treatment-of-glaucoma\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5Mzk0OSMzODQ4NTg1IzIwODc3MjU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5Mzk0OSMzODQ4NTg1IzIwODc3MjU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tearclear-announces-successful-completion-of-pre-ind-meeting-with-the-fda-for-a-preservative-free-multi-dose-delivery-of-latanoprost-for-the-treatment-of-glaucoma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TearClear Announces Successful Completion of Pre-IND Meeting with the FDA for a Preservative Free Multi-Dose Delivery of Latanoprost for the Treatment of Glaucoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"TearClear Announces Successful Completion of Pre-IND Meeting with the FDA for a Preservative Free Multi-Dose Delivery of Latanoprost for the Treatment of Glaucoma - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/tearclear-announces-successful-completion-of-pre-ind-meeting-with-the-fda-for-a-preservative-free-multi-dose-delivery-of-latanoprost-for-the-treatment-of-glaucoma\/","og_locale":"en_US","og_type":"article","og_title":"TearClear Announces Successful Completion of Pre-IND Meeting with the FDA for a Preservative Free Multi-Dose Delivery of Latanoprost for the Treatment of Glaucoma - Market Newsdesk","og_description":"Prepared to file an IND in mid-2021 via the 505(b)(2) NDA pathway BOSTON, Dec. 01, 2020 (GLOBE NEWSWIRE) &#8212; TearClear, an emerging ophthalmic pharmaceutical company, today announced successful completion of pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding the development plan for the preservative free multi-dose delivery of a proprietary Latanoprost formulation, including the clinical study design for the registration study. \u201cWe are pleased with the outcome of the Pre-IND meeting and look forward to preparing the IND filing and commencing our pivotal registration trial in 2021,\u201d said\u00a0Robert Dempsey, Chief Executive Officer, TearClear. &#8220;The successful completion of this engagement with the FDA is an important milestone for the company and provides clarity and confidence &hellip; Continue reading \"TearClear Announces Successful Completion of Pre-IND Meeting with the FDA for a Preservative Free Multi-Dose Delivery of Latanoprost for the Treatment of Glaucoma\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/tearclear-announces-successful-completion-of-pre-ind-meeting-with-the-fda-for-a-preservative-free-multi-dose-delivery-of-latanoprost-for-the-treatment-of-glaucoma\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-01T11:03:16+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5Mzk0OSMzODQ4NTg1IzIwODc3MjU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tearclear-announces-successful-completion-of-pre-ind-meeting-with-the-fda-for-a-preservative-free-multi-dose-delivery-of-latanoprost-for-the-treatment-of-glaucoma\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tearclear-announces-successful-completion-of-pre-ind-meeting-with-the-fda-for-a-preservative-free-multi-dose-delivery-of-latanoprost-for-the-treatment-of-glaucoma\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"TearClear Announces Successful Completion of Pre-IND Meeting with the FDA for a Preservative Free Multi-Dose Delivery of Latanoprost for the Treatment of Glaucoma","datePublished":"2020-12-01T11:03:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tearclear-announces-successful-completion-of-pre-ind-meeting-with-the-fda-for-a-preservative-free-multi-dose-delivery-of-latanoprost-for-the-treatment-of-glaucoma\/"},"wordCount":421,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tearclear-announces-successful-completion-of-pre-ind-meeting-with-the-fda-for-a-preservative-free-multi-dose-delivery-of-latanoprost-for-the-treatment-of-glaucoma\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5Mzk0OSMzODQ4NTg1IzIwODc3MjU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tearclear-announces-successful-completion-of-pre-ind-meeting-with-the-fda-for-a-preservative-free-multi-dose-delivery-of-latanoprost-for-the-treatment-of-glaucoma\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/tearclear-announces-successful-completion-of-pre-ind-meeting-with-the-fda-for-a-preservative-free-multi-dose-delivery-of-latanoprost-for-the-treatment-of-glaucoma\/","name":"TearClear Announces Successful Completion of Pre-IND Meeting with the FDA for a Preservative Free Multi-Dose Delivery of Latanoprost for the Treatment of Glaucoma - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tearclear-announces-successful-completion-of-pre-ind-meeting-with-the-fda-for-a-preservative-free-multi-dose-delivery-of-latanoprost-for-the-treatment-of-glaucoma\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tearclear-announces-successful-completion-of-pre-ind-meeting-with-the-fda-for-a-preservative-free-multi-dose-delivery-of-latanoprost-for-the-treatment-of-glaucoma\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5Mzk0OSMzODQ4NTg1IzIwODc3MjU=","datePublished":"2020-12-01T11:03:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tearclear-announces-successful-completion-of-pre-ind-meeting-with-the-fda-for-a-preservative-free-multi-dose-delivery-of-latanoprost-for-the-treatment-of-glaucoma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/tearclear-announces-successful-completion-of-pre-ind-meeting-with-the-fda-for-a-preservative-free-multi-dose-delivery-of-latanoprost-for-the-treatment-of-glaucoma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tearclear-announces-successful-completion-of-pre-ind-meeting-with-the-fda-for-a-preservative-free-multi-dose-delivery-of-latanoprost-for-the-treatment-of-glaucoma\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5Mzk0OSMzODQ4NTg1IzIwODc3MjU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5Mzk0OSMzODQ4NTg1IzIwODc3MjU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tearclear-announces-successful-completion-of-pre-ind-meeting-with-the-fda-for-a-preservative-free-multi-dose-delivery-of-latanoprost-for-the-treatment-of-glaucoma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"TearClear Announces Successful Completion of Pre-IND Meeting with the FDA for a Preservative Free Multi-Dose Delivery of Latanoprost for the Treatment of Glaucoma"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/390247","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=390247"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/390247\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=390247"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=390247"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=390247"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}